From: A systematic review of the budget impact analyses for antitumor drugs of lung cancer
First author | Perspective | Target population estimate | 1–5 years of budget time horizon | Hypothetical scenario | Comparator | Frame description | Data collection and sources | Validation | Sensitivity analysis |
---|---|---|---|---|---|---|---|---|---|
Carlson [31] | √ | √ | √ | √ | √ |  | √ |  | √ |
Farsai [39] | √ | √ | √ | √ | √ |  | √ |  | √ |
Sumitra [40] | √ | √ | √ | √ | √ | √ | √ |  | √ |
Preeti [32] | √ | √ | √ | √ | √ | √ | √ |  | √ |
Lisa [33] | √ | √ | √ | √ | √ | √ | √ | √ |  |
Mengyuan [41] | √ | √ | √ | √ | √ | √ | √ |  | √ |
Sumitra [42] | √ | √ | √ | √ | √ |  | √ |  | √ |
Daniel [34] | √ | √ | √ | √ | √ | √ | √ |  | √ |
Jan [43] | √ | √ | √ | √ | √ | √ | √ | √ | √ |
Pedro [44] | √ | √ | √ |  |  |  | √ |  |  |
Christopher [35] | √ | √ | √ | √ | √ | √ | √ |  | √ |
Jonathan [36] | √ | √ | √ | √ | √ | √ | √ |  | √ |
Xueyan [45] | √ | √ | √ | √ | √ | √ | √ |  | √ |
Jie [46] | √ | √ | √ | √ | √ |  | √ |  | √ |